



## Clinical trial results:

### A 52-week, Randomised, Double-blind, Placebo-controlled, Parallel group, Multi-centre Study of the Efficacy and Safety of GSK3511294 Adjunctive Therapy in Adult and Adolescent Participants with Severe Uncontrolled Asthma with an Eosinophilic Phenotype

#### Summary

EudraCT number	2020-003611-10
Trial protocol	FR CZ PL IT ES HU
Global end of trial date	11 April 2024

#### Results information

Result version number	v1
This version publication date	24 October 2024
First version publication date	24 October 2024

#### Trial information

##### Trial identification

Sponsor protocol code	213744
-----------------------	--------

##### Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	NCT04718103
WHO universal trial number (UTN)	-

Notes:

#### Sponsors

Sponsor organisation name	GlaxoSmithKline
Sponsor organisation address	980 Great West Road, Brentford, Middlesex, United Kingdom, TW8 9GS
Public contact	GSK Response Center, GlaxoSmithKline, 1 8664357343, GSKClinicalSupportHD@gsk.com
Scientific contact	GSK Response Center, GlaxoSmithKline, 1 8664357343, GSKClinicalSupportHD@gsk.com

Notes:

#### Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	No

Notes:

## Results analysis stage

Analysis stage	Final
Date of interim/final analysis	20 May 2024
Is this the analysis of the primary completion data?	Yes
Primary completion date	11 April 2024
Global end of trial reached?	Yes
Global end of trial date	11 April 2024
Was the trial ended prematurely?	No

Notes:

## General information about the trial

Main objective of the trial:

To evaluate the efficacy of GSK3511294 100 mg (SC) every 26 weeks versus placebo in participants with severe uncontrolled asthma with an eosinophilic phenotype on top of existing asthma therapy.

Protection of trial subjects:

NA

Background therapy: -

Evidence for comparator: -

Actual start date of recruitment	04 February 2021
Long term follow-up planned	No
Independent data monitoring committee (IDMC) involvement?	Yes

Notes:

## Population of trial subjects

### Subjects enrolled per country

Country: Number of subjects enrolled	Taiwan: 13
Country: Number of subjects enrolled	Japan: 71
Country: Number of subjects enrolled	Canada: 2
Country: Number of subjects enrolled	Australia: 5
Country: Number of subjects enrolled	United States: 139
Country: Number of subjects enrolled	Poland: 60
Country: Number of subjects enrolled	Spain: 45
Country: Number of subjects enrolled	Italy: 14
Country: Number of subjects enrolled	Hungary: 14
Country: Number of subjects enrolled	Czechia: 25
Country: Number of subjects enrolled	France: 9
Worldwide total number of subjects	397
EEA total number of subjects	167

Notes:

### Subjects enrolled per age group

In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0

Infants and toddlers (28 days-23 months)	0
Children (2-11 years)	0
Adolescents (12-17 years)	22
Adults (18-64 years)	277
From 65 to 84 years	98
85 years and over	0

## Subject disposition

### Recruitment

Recruitment details:

Of 397 participants who were randomized, 380 participants were included in Full analysis set (FAS) population. FAS included all randomized participants who received at least 1 dose of study drug excluding 12 participants from 2 Good Clinical Practice (GCP) violation sites and 5 participants were randomized in error & did not receive any study drug.

### Pre-assignment

Screening details:

In this study, out of 663 participants screened, 397 participants were enrolled/randomized to the study. In total 380 participants received at least one dose of study drug & included in the FAS.

### Period 1

Period 1 title	Overall Study (overall period)
Is this the baseline period?	Yes
Allocation method	Randomised - controlled
Blinding used	Double blind
Roles blinded	Subject, Investigator, Assessor

### Arms

Are arms mutually exclusive?	Yes
<b>Arm title</b>	GSK3511294

Arm description:

Participants received a 100 milligram (mg) dose of GSK3511294 subcutaneous (SC) injection once every 26 weeks (week 0 and week 26). Participants were to be maintained on their existing baseline maintenance asthma standard of care (SOC) treatment throughout the study.

Arm type	Experimental
Investigational medicinal product name	GSK3511294
Investigational medicinal product code	
Other name	Depemokimab
Pharmaceutical forms	Solution for injection
Routes of administration	Subcutaneous use

Dosage and administration details:

100 milligram (mg) per milligram once every 26 weeks

<b>Arm title</b>	Placebo
------------------	---------

Arm description:

Participants received placebo SC injection once every 26 weeks (week 0 and week 26). Participants were to be maintained on their existing baseline maintenance asthma standard of care (SOC) treatment throughout the study.

Arm type	Placebo
Investigational medicinal product name	Placebo
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Solution for injection
Routes of administration	Subcutaneous use

Dosage and administration details:

Matching Placebo once every 26 weeks

<b>Number of subjects in period 1<sup>[1]</sup></b>	<b>GSK3511294</b>	<b>Placebo</b>
Started	252	128
Completed	233	117
Not completed	19	11
Physician decision	2	-
Consent withdrawn by subject	10	6
Adverse event, non-fatal	1	1
Pregnancy	-	1
Lost to follow-up	2	2
Lack of efficacy	4	1

---

Notes:

[1] - The number of subjects reported to be in the baseline period are not the same as the worldwide number enrolled in the trial. It is expected that these numbers will be the same.

Justification: Of 17 participants who were randomized, 12 participants from 2 sites were excluded from the full analysis population due to data integrity concerns & GCP violations, and 5 randomized participants did not receive any study intervention, hence not included in the FAS population.

## Baseline characteristics

### Reporting groups

Reporting group title	GSK3511294
-----------------------	------------

Reporting group description:

Participants received a 100 milligram (mg) dose of GSK3511294 subcutaneous (SC) injection once every 26 weeks (week 0 and week 26). Participants were to be maintained on their existing baseline maintenance asthma standard of care (SOC) treatment throughout the study.

Reporting group title	Placebo
-----------------------	---------

Reporting group description:

Participants received placebo SC injection once every 26 weeks (week 0 and week 26). Participants were to be maintained on their existing baseline maintenance asthma standard of care (SOC) treatment throughout the study.

Reporting group values	GSK3511294	Placebo	Total
Number of subjects	252	128	380
Age categorical Units: Subjects			
In utero	0	0	0
Preterm newborn infants (gestational age < 37 wks)	0	0	0
Newborns (0-27 days)	0	0	0
Infants and toddlers (28 days-23 months)	0	0	0
Children (2-11 years)	0	0	0
Adolescents (12-17 years)	12	10	22
Adults (18-64 years)	169	93	262
From 65-84 years	71	25	96
85 years and over	0	0	0
Age continuous Units: years			
arithmetic mean	53.6	51.2	
standard deviation	± 16.00	± 16.58	-
Sex: Female, Male Units: Participants			
Female	160	81	241
Male	92	47	139
Race/Ethnicity, Customized Units: Subjects			
Asian	52	23	75
White	181	91	272
De-identified	19	14	33

## End points

### End points reporting groups

Reporting group title	GSK3511294
Reporting group description: Participants received a 100 milligram (mg) dose of GSK3511294 subcutaneous (SC) injection once every 26 weeks (week 0 and week 26). Participants were to be maintained on their existing baseline maintenance asthma standard of care (SOC) treatment throughout the study.	
Reporting group title	Placebo
Reporting group description: Participants received placebo SC injection once every 26 weeks (week 0 and week 26). Participants were to be maintained on their existing baseline maintenance asthma standard of care (SOC) treatment throughout the study.	

### Primary: Annualized Rate of Clinically Significant Exacerbations up to 52 Weeks

End point title	Annualized Rate of Clinically Significant Exacerbations up to 52 Weeks
End point description: Clinically significant exacerbations recorded were defined as worsening of asthma requiring the use of systemic corticosteroids (CS) [such as intramuscular (IM), intravenous (IV) or oral] and/or hospitalization and/or Emergency Department (ED) visit. For all participants, IV or oral steroids (e.g., prednisone) for at least 3 days or a single IM corticosteroid dose is required. For participants on maintenance systemic corticosteroids, at least double the existing maintenance dose for at least 3 days is required. Exacerbations recorded in the eCRF were considered as verified clinically significant exacerbations and included in the primary analysis. Exacerbations separated by less than 7 days was treated as a continuation of the same exacerbation. The analysis was performed on the Full Analysis Set population.	
End point type	Primary
End point timeframe: Up to Week 52	

End point values	GSK3511294	Placebo		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	252	128		
Units: Exacerbation per participant per year				
number (confidence interval 95%)	0.56 (0.44 to 0.70)	1.08 (0.83 to 1.41)		

### Statistical analyses

Statistical analysis title	Statistical Analysis 1
Statistical analysis description: To demonstrate the superiority of GSK3511294 100 mg SC + SoC following two doses (at Week 0 and at Week 26) compared with placebo + SoC, assessed by the annualized rate of clinically significant exacerbations measured over the study intervention period of 52 weeks.	
Comparison groups	GSK3511294 v Placebo

Number of subjects included in analysis	380
Analysis specification	Pre-specified
Analysis type	superiority <sup>[1]</sup>
P-value	< 0.001
Method	Negative binomial distribution
Parameter estimate	Rate Ratio
Point estimate	0.52
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.36
upper limit	0.73

Notes:

[1] - Analysis performed using a generalized linear model assuming a negative binomial distribution and covariates of treatment group, baseline ICS dose (medium or high), exacerbation history (2, 3, 4+), geographical region and baseline pre-bronchodilator percent predicted Forced Expiratory Volume in one second (FEV1) and offset of log (total time in the study in years).

## Secondary: Change From Baseline in St. George's Respiratory Questionnaire (SGRQ) Total Score at Week 52

End point title	Change From Baseline in St. George's Respiratory Questionnaire (SGRQ) Total Score at Week 52
-----------------	--

End point description:

The SGRQ is a 50-item patient-reported outcome tool used to measure Quality of Life in participants with airway obstruction diseases. The questions are designed to be self-completed by the participant. The total score was calculated by the symptom score, activity and impact score; and summarizing the impact of the disease on overall health status. Scores are expressed as a percentage of overall impairment where 100 representing worst possible health status and 0 indicating best possible health status. Higher scores also indicating greater impairment of quality of life. Change from Baseline was defined as value at the indicated time point minus Baseline value. The analysis was performed on the FAS population that included all randomized participants who received at least 1 dose of study intervention excluding participants from 2 GCP violation sites.

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline (Day 1) and Week 52

End point values	GSK3511294	Placebo		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	246	124		
Units: Scores on a scale				
least squares mean (standard error)	-14.80 (± 1.041)	-12.49 (± 1.455)		

## Statistical analyses

Statistical analysis title	Statistical Analysis 2
----------------------------	------------------------

Statistical analysis description:

To demonstrate the superiority of GSK3511294 100 mg SC + SoC following two doses (at Week 0 and at Week 26) compared with placebo + SoC, assessed by SGRQ Total Score measured over the study intervention period of 52 weeks.

Comparison groups	Placebo v GSK3511294
-------------------	----------------------



Number of subjects included in analysis	370
Analysis specification	Pre-specified
Analysis type	superiority <sup>[2]</sup>
P-value	= 0.2
Method	Mixed Models Repeated Measures (MMRM)
Parameter estimate	Difference in Least-Square Means
Point estimate	-2.31
Confidence interval	
level	95 %
sides	2-sided
lower limit	-5.84
upper limit	1.23

Notes:

[2] - Analysis performed using a repeated measures model with covariates of treatment group, baseline ICS dose (medium or high), exacerbation history (2, 3, 4+), geographical region, baseline SGRQ total score, baseline pre- bronchodilator percent predicted FEV1, visit, visit by baseline SGRQ total score and visit by treatment group.

## Secondary: Change From Baseline in Asthma Control Questionnaire-5 (ACQ-5) Score at Week 52

End point title	Change From Baseline in Asthma Control Questionnaire-5 (ACQ-5) Score at Week 52
-----------------	---

End point description:

The ACQ-5 is a five-item questionnaire developed as a measure of participants asthma symptom control. The questions are designed to be self-completed by the participant. The 5 questions enquired to recall their how their asthma had been during the previous week and to respond about the frequency and/or severity of symptoms (nocturnal awakening, waking in the morning, activity limitation, shortness of breath and wheezing). The overall ACQ-5 response option is the mean score of all 5 questions representing 0 with no impairment/limitation and 6 as total impairment/ limitation. Higher scores indicated more limitations and lower score with better asthma control. Change from Baseline was defined as value at the indicated time point minus Baseline value. The analysis was performed on the FAS population that included all randomized participants who received at least 1 dose of study intervention excluding participants from 2 GCP violation sites.

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline (Day 1) and Week 52

End point values	GSK3511294	Placebo		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	246	124		
Units: Scores on a scale				
least squares mean (standard error)	-0.81 (± 0.065)	-0.70 (± 0.091)		

## Statistical analyses

Statistical analysis title	Statistical Analysis 3
----------------------------	------------------------

Statistical analysis description:

Analysis performed using a repeated measures model with covariates of treatment group, baseline ICS dose (medium or high), exacerbation history (2, 3, 4+), geographical region, baseline ACQ-5 score, baseline pre-bronchodilator percent predicted FEV1, visit, visit by baseline ACQ-5 score and visit by

treatment group.

Comparison groups	GSK3511294 v Placebo
Number of subjects included in analysis	370
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.333
Method	Mixed Models Repeated Measures (MMRM)
Parameter estimate	Difference in Least-Square Means
Point estimate	-0.11
Confidence interval	
level	95 %
sides	2-sided
lower limit	-0.33
upper limit	0.11

### Secondary: Change From Baseline in Pre-Bronchodilator Forced Expiratory Volume in One Second (FEV1) At Week 52

End point title	Change From Baseline in Pre-Bronchodilator Forced Expiratory Volume in One Second (FEV1) At Week 52
End point description: Forced Expiratory Volume in One Second (FEV1) is defined as the maximum volume of air that can be forced out in one second after taking a deep breath by a person and will be measured by spirometry. Change from Baseline in clinic pre-bronchodilator FEV1 was determined. Change from Baseline was defined as value at the indicated time point minus Baseline value. The analysis was performed on the FAS population that included all randomized participants who received at least 1 dose of study intervention excluding participants from 2 GCP violation sites.	
End point type	Secondary
End point timeframe: Baseline (Day 1) and Week 52	

End point values	GSK3511294	Placebo		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	239	119		
Units: Liters (L)				
least squares mean (standard error)	0.240 (± 0.0286)	0.184 (± 0.0407)		

### Statistical analyses

Statistical analysis title	Statistical Analysis 4
Statistical analysis description: Analysis performed using a repeated measures model with covariates of treatment group, baseline ICS dose (medium or high), exacerbation history (2, 3, 4+), geographical region, baseline pre-bronchodilator FEV1, visit, visit by baseline pre-bronchodilator FEV1 and visit by treatment group.	
Comparison groups	GSK3511294 v Placebo

Number of subjects included in analysis	358
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.267
Method	Mixed Models Repeated Measures (MMRM)
Parameter estimate	Difference in Least-Square Means
Point estimate	0.056
Confidence interval	
level	95 %
sides	2-sided
lower limit	-0.043
upper limit	0.154

## Secondary: Change From Baseline in Asthma Nighttime Symptom Diary (ANSD) Weekly Mean Score at Week 52

End point title	Change From Baseline in Asthma Nighttime Symptom Diary (ANSD) Weekly Mean Score at Week 52
-----------------	--

End point description:

The ANSD is a 6-item self-administered patient reported diary developed by Patient Related Outcomes (PRO) Consortium's Asthma Working Group to facilitate comprehensive and reliable assessment of asthma symptoms from a participant's perspective. Participants were required to rate the severity of symptoms in 3 categories: breathing symptoms (wheezing, shortness of breath), chest symptoms (chest tightness, chest pain) & cough. The ANSD was to be completed before going to bed & refers to asthma symptoms during the day. Symptoms are rated at their worst using an 11-point numeric rating scale ranging from 0 (None) to 10 (As bad as you can imagine). Higher scores indicate more severe symptoms. Mean daily scores of ANSD was calculated by weekly intervals. The baseline was defined as average score from Days -7 to -1 inclusive (at least 4 days must be non-missing). Change from Baseline as value at each time point minus Baseline value. The FAS included with 1 ANSD questionnaire was administered.

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline to Week 52

End point values	GSK3511294	Placebo		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	232	117		
Units: Scores on a scale				
least squares mean (standard error)				
ANSD Mean Score	-1.18 (± 0.091)	-0.97 (± 0.127)		

## Statistical analyses

Statistical analysis title	Statistical Analysis for ANSD
----------------------------	-------------------------------

Statistical analysis description:

Analysis performed using a repeated measures model with covariates of treatment group, baseline ICS dose (medium or high), exacerbation history (2, 3, 4+), geographical region, baseline ANSD weekly mean score, baseline pre-bronchodilator percent predicted FEV1, visit, visit by baseline ANSD weekly

mean score and visit by treatment group.

Comparison groups	GSK3511294 v Placebo
Number of subjects included in analysis	349
Analysis specification	Pre-specified
Analysis type	superiority <sup>[3]</sup>
P-value	= 0.173
Method	Mixed Models Repeated Measures (MMRM)
Parameter estimate	Difference in Least square means
Point estimate	-0.21
Confidence interval	
level	95 %
sides	2-sided
lower limit	-0.52
upper limit	0.09

Notes:

[3] - ANSD at Week 52

### Secondary: Change From Baseline in Asthma Daily Symptom Diary (ADSD) Weekly Mean Score at Week 52

End point title	Change From Baseline in Asthma Daily Symptom Diary (ADSD) Weekly Mean Score at Week 52
-----------------	--

End point description:

The ADSD is a 6-item self-administered patient reported diary developed by Patient Related Outcomes (PRO) Consortium's Asthma Working Group to facilitate comprehensive and reliable assessment of asthma symptoms from a participant's perspective. Participants were required to rate the severity of symptoms in 3 categories: breathing symptoms (wheezing, shortness of breath), chest symptoms (chest tightness, chest pain) & cough. The ADSD was to be completed before going to bed & refers to asthma symptoms during the day. Symptoms are rated at their worst using an 11-point numeric rating scale ranging from 0 (None) to 10 (As bad as you can imagine). Higher scores indicate more severe symptoms. Mean daily scores of ADSD was calculated by weekly intervals. The baseline was defined as average score from Days -7 to -1 inclusive (at least 4 days must be non-missing). Change from Baseline as value at each time point minus Baseline value. The FAS included with 1 ADSD questionnaire was administered.

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline to Week 52

End point values	GSK3511294	Placebo		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	249	126		
Units: Scores on a Scale				
least squares mean (standard error)				
ADSD Mean Score	-1.13 (± 0.080)	-0.93 (± 0.112)		

### Statistical analyses

Statistical analysis title	Statistical Analysis for ADSD
----------------------------	-------------------------------

#### Statistical analysis description:

Analysis performed using a repeated measures model with covariates of treatment group, baseline ICS dose (medium or high), exacerbation history (2, 3, 4+), geographical region, baseline ADSD weekly mean score, baseline pre-bronchodilator percent predicted FEV1, visit, visit by baseline ADSD weekly mean score and visit by treatment group.

Comparison groups	GSK3511294 v Placebo
Number of subjects included in analysis	375
Analysis specification	Pre-specified
Analysis type	superiority <sup>[4]</sup>
P-value	= 0.138
Method	Mixed Models Repeated Measures (MMRM)
Parameter estimate	Difference in Least Square Means
Point estimate	-0.21
Confidence interval	
level	95 %
sides	2-sided
lower limit	-0.48
upper limit	0.07

Notes:

[4] - ADSD at Week 52

#### **Secondary: Annualized Rate of Exacerbations Requiring Hospitalization and/or Emergency Department (ED) Visit up to 52 Weeks**

End point title	Annualized Rate of Exacerbations Requiring Hospitalization and/or Emergency Department (ED) Visit up to 52 Weeks
-----------------	--

End point description:

Annualized Rate of exacerbations of asthma were defined as worsening of asthma which required use of systemic corticosteroids (CSs) and/or hospitalization and/or ED visit. For all participants, IV or oral steroids (e.g., prednisone) for at least 3 days or a single IM CS dose is required. For participants on maintenance systemic CSs, at least double the existing maintenance dose for at least 3 days is required. Exacerbations separated by less than 7 days will be treated as a continuation of the same exacerbation. Exacerbations Requiring Hospitalization and/or ED Visit are reported here. The analysis was performed on the FAS population that included all randomized participants who received at least 1 dose of study intervention excluding participants from 2 GCP violation sites.

End point type	Secondary
----------------	-----------

End point timeframe:

Up to Week 52

End point values	GSK3511294	Placebo		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	252	128		
Units: Exacerbation per participant per year				
number (confidence interval 95%)	0.05 (0.02 to 0.09)	0.11 (0.05 to 0.22)		

#### **Statistical analyses**

<b>Statistical analysis title</b>	Statistical Analysis
Statistical analysis description:	
Analysis performed using a generalized linear model assuming a negative binomial distribution and covariates of treatment group, baseline ICS dose (medium or high), exacerbation history (2, 3, 4+), geographical region and baseline pre-bronchodilator percent predicted FEV1.	
Comparison groups	GSK3511294 v Placebo
Number of subjects included in analysis	380
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.087
Method	Negative binomial distribution
Parameter estimate	Rate Ratio
Point estimate	0.42
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.16
upper limit	1.13

## Adverse events

### Adverse events information

Timeframe for reporting adverse events:

Serious adverse events (SAEs), deaths and non-serious adverse events (non-SAEs) were collected from the start of the study intervention (Day 1) till follow up week 56.

Adverse event reporting additional description:

Safety analysis set included all participants who received at least 1 dose of study drug excluding participants from 2 GCP violation sites. One participant was randomized to receive GSK3511294 but received 1 dose of placebo in error & did not receive 2nd planned dose. This participant was included in actual placebo group for analysis.

Assessment type	Systematic
-----------------	------------

### Dictionary used

Dictionary name	MedDRA
-----------------	--------

Dictionary version	26.1
--------------------	------

### Reporting groups

Reporting group title	Placebo
-----------------------	---------

Reporting group description:

Participants received placebo SC injection once every 26 weeks (week 0 and week 26). Participants were to be maintained on their existing baseline maintenance asthma SOC treatment throughout the study.

Reporting group title	GSK3511294
-----------------------	------------

Reporting group description:

Participants received a 100 mg dose of GSK3511294 SC injection once every 26 weeks (week 0 and week 26). Participants were to be maintained on their existing baseline maintenance asthma SOC treatment throughout the study.

Serious adverse events	Placebo	GSK3511294	
Total subjects affected by serious adverse events			
subjects affected / exposed	13 / 129 (10.08%)	19 / 251 (7.57%)	
number of deaths (all causes)	0	0	
number of deaths resulting from adverse events			
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Small intestine adenocarcinoma			
subjects affected / exposed	0 / 129 (0.00%)	1 / 251 (0.40%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Ovarian cancer			
subjects affected / exposed	0 / 129 (0.00%)	1 / 251 (0.40%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Metastases to peritoneum			

subjects affected / exposed	0 / 129 (0.00%)	1 / 251 (0.40%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Basal cell carcinoma			
subjects affected / exposed	0 / 129 (0.00%)	1 / 251 (0.40%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Immune system disorders			
Anaphylactic reaction			
subjects affected / exposed	1 / 129 (0.78%)	0 / 251 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Reproductive system and breast disorders			
Benign prostatic hyperplasia			
subjects affected / exposed	1 / 129 (0.78%)	0 / 251 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Respiratory, thoracic and mediastinal disorders			
Asthma			
subjects affected / exposed	6 / 129 (4.65%)	7 / 251 (2.79%)	
occurrences causally related to treatment / all	0 / 8	0 / 12	
deaths causally related to treatment / all	0 / 0	0 / 0	
Investigations			
Alanine aminotransferase abnormal			
subjects affected / exposed	0 / 129 (0.00%)	1 / 251 (0.40%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Blood bilirubin abnormal			
subjects affected / exposed	0 / 129 (0.00%)	1 / 251 (0.40%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Injury, poisoning and procedural complications			
Accidental exposure to product			



subjects affected / exposed	0 / 129 (0.00%)	1 / 251 (0.40%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Congenital, familial and genetic disorders			
Phimosi			
subjects affected / exposed	1 / 129 (0.78%)	0 / 251 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cardiac disorders			
Coronary artery disease			
subjects affected / exposed	1 / 129 (0.78%)	0 / 251 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Nervous system disorders			
Epilepsy			
subjects affected / exposed	0 / 129 (0.00%)	1 / 251 (0.40%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Headache			
subjects affected / exposed	0 / 129 (0.00%)	1 / 251 (0.40%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Seizure			
subjects affected / exposed	0 / 129 (0.00%)	1 / 251 (0.40%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cerebral infarction			
subjects affected / exposed	0 / 129 (0.00%)	1 / 251 (0.40%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastrointestinal disorders			
Abdominal pain			

subjects affected / exposed	0 / 129 (0.00%)	1 / 251 (0.40%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Large intestine polyp			
subjects affected / exposed	0 / 129 (0.00%)	1 / 251 (0.40%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Renal and urinary disorders			
Nephrolithiasis			
subjects affected / exposed	1 / 129 (0.78%)	0 / 251 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Ureterolithiasis			
subjects affected / exposed	1 / 129 (0.78%)	0 / 251 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Musculoskeletal and connective tissue disorders			
Tenosynovitis stenosans			
subjects affected / exposed	0 / 129 (0.00%)	1 / 251 (0.40%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Osteochondritis			
subjects affected / exposed	0 / 129 (0.00%)	1 / 251 (0.40%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Foot deformity			
subjects affected / exposed	0 / 129 (0.00%)	1 / 251 (0.40%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Spondylolisthesis			
subjects affected / exposed	1 / 129 (0.78%)	0 / 251 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	

Infections and infestations COVID-19 subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	0 / 129 (0.00%) 0 / 0 0 / 0	1 / 251 (0.40%) 0 / 1 0 / 0	
Pneumonia subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	2 / 129 (1.55%) 0 / 2 0 / 0	0 / 251 (0.00%) 0 / 0 0 / 0	
Sepsis subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	1 / 129 (0.78%) 0 / 1 0 / 0	0 / 251 (0.00%) 0 / 0 0 / 0	

Frequency threshold for reporting non-serious adverse events: 3 %

<b>Non-serious adverse events</b>	Placebo	GSK3511294	
Total subjects affected by non-serious adverse events subjects affected / exposed	80 / 129 (62.02%)	138 / 251 (54.98%)	
Vascular disorders Hypertension subjects affected / exposed occurrences (all)	7 / 129 (5.43%) 8	7 / 251 (2.79%) 7	
Nervous system disorders Headache subjects affected / exposed occurrences (all) Dizziness subjects affected / exposed occurrences (all)	10 / 129 (7.75%) 12 1 / 129 (0.78%) 1	20 / 251 (7.97%) 30 8 / 251 (3.19%) 10	
Gastrointestinal disorders Diarrhoea subjects affected / exposed occurrences (all) Nausea	3 / 129 (2.33%) 3	8 / 251 (3.19%) 10	

subjects affected / exposed occurrences (all)	4 / 129 (3.10%) 4	1 / 251 (0.40%) 1	
Respiratory, thoracic and mediastinal disorders			
Rhinitis allergic subjects affected / exposed occurrences (all)	3 / 129 (2.33%) 3	18 / 251 (7.17%) 23	
Oropharyngeal pain subjects affected / exposed occurrences (all)	5 / 129 (3.88%) 5	3 / 251 (1.20%) 3	
Musculoskeletal and connective tissue disorders			
Arthralgia subjects affected / exposed occurrences (all)	5 / 129 (3.88%) 5	14 / 251 (5.58%) 16	
Back pain subjects affected / exposed occurrences (all)	6 / 129 (4.65%) 7	7 / 251 (2.79%) 7	
Infections and infestations			
Urinary tract infection subjects affected / exposed occurrences (all)	4 / 129 (3.10%) 5	6 / 251 (2.39%) 8	
Upper respiratory tract infection subjects affected / exposed occurrences (all)	6 / 129 (4.65%) 6	21 / 251 (8.37%) 29	
Sinusitis subjects affected / exposed occurrences (all)	6 / 129 (4.65%) 7	11 / 251 (4.38%) 11	
Rhinitis subjects affected / exposed occurrences (all)	5 / 129 (3.88%) 6	7 / 251 (2.79%) 7	
Respiratory tract infection subjects affected / exposed occurrences (all)	8 / 129 (6.20%) 4	5 / 251 (1.99%) 5	
Pharyngitis subjects affected / exposed occurrences (all)	1 / 129 (0.78%) 1	10 / 251 (3.98%) 10	
Bronchitis			

subjects affected / exposed	12 / 129 (9.30%)	10 / 251 (3.98%)	
occurrences (all)	12	11	
COVID-19			
subjects affected / exposed	19 / 129 (14.73%)	36 / 251 (14.34%)	
occurrences (all)	20	38	
Influenza			
subjects affected / exposed	9 / 129 (6.98%)	5 / 251 (1.99%)	
occurrences (all)	9	5	
Lower respiratory tract infection			
subjects affected / exposed	5 / 129 (3.88%)	4 / 251 (1.59%)	
occurrences (all)	8	5	
Nasopharyngitis			
subjects affected / exposed	27 / 129 (20.93%)	33 / 251 (13.15%)	
occurrences (all)	44	45	

## More information

### Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? Yes

Date	Amendment
17 August 2021	Amendment 01
05 April 2022	Amendment 02

Notes:

---

### Interruptions (globally)

Were there any global interruptions to the trial? No

### Limitations and caveats

None reported

---

### Online references

<http://www.ncbi.nlm.nih.gov/pubmed/39248309>